Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients

被引:94
作者
de Glas, Nienke A. [1 ,2 ]
Kiderlen, Mandy [1 ,2 ]
Vandenbroucke, Jan P. [3 ]
de Craen, Anton J. M. [2 ]
Portielje, Johanneke E. A. [5 ]
de Velde, Cornelis J. H. van [1 ]
Liefers, Gerrit-Jan [1 ]
Bastiaannet, Esther [1 ,2 ]
Le Cessie, Saskia [3 ,4 ]
机构
[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Postzone K6-R,POB 9600, NL-2300 RC Leiden, Netherlands
[5] Haga Hosp, Dept Med Oncol, The Hague, Netherlands
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2016年 / 108卷 / 05期
关键词
KAPLAN-MEIER METHOD; SUBDISTRIBUTION; MODELS; IMPACT; DEATH; WOMEN;
D O I
10.1093/jnci/djv366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An important consideration in studies that use cause-specific endpoints such as cancer-specific survival or disease recurrence is that risk of dying from another cause before experiencing the event of interest is generally much higher in older patients. Such competing events are of major importance in the design and analysis of studies with older patients, as a patient who dies from another cause before the event of interest cannot reach the endpoint. In this Commentary, we present several clinical examples of research questions in a population-based cohort of older breast cancer patients with a high frequency of competing events and discuss implications of choosing models that deal with competing risks in different ways. We show that in populations with high frequency of competing events, it is important to consider which method is most appropriate to estimate cause-specific endpoints. We demonstrate that when calculating absolute cause-specific risks the Kaplan-Meier method overestimates risk of the event of interest and that the cumulative incidence competing risks (CICR) method, which takes competing risks into account, should be used instead. Two approaches are commonly used to model the association between prognostic factors and cause-specific survival: the Cox proportional hazards model and the Fine and Gray model. We discuss both models and show that in etiologic research the Cox Proportional Hazards model is recommended, while in predictive research the Fine and Gray model is often more appropriate. In conclusion, in studies with cause-specific endpoints in populations with a high frequency of competing events, researchers should carefully choose the most appropriate statistical method to prevent incorrect interpretation of results.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Modeling the survival in patients with HIV by the presence of competing risks for death: sub-distribution and cause-specific hazard approach
    Ghodratollah Roshanaei
    Razieh Imani
    Jalal Poorolajal
    Mohammad Asghari-Jafarabadi
    Seyede Momeneh Mohammadi
    Journal of Public Health, 2022, 30 : 1675 - 1683
  • [22] Modeling the survival in patients with HIV by the presence of competing risks for death: sub-distribution and cause-specific hazard approach
    Roshanaei, Ghodratollah
    Imani, Razieh
    Poorolajal, Jalal
    Asghari-Jafarabadi, Mohammad
    Mohammadi, Seyede Momeneh
    JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2022, 30 (07): : 1675 - 1683
  • [23] Prognostic factors in Asian and white American patients with cervical cancer, considering competing risks
    Hou, Y.
    Guo, S.
    Lyu, J.
    Lu, Z.
    Yang, Z.
    Liu, D.
    Chen, Z.
    CURRENT ONCOLOGY, 2019, 26 (03) : E277 - E285
  • [24] Clinical Management Update: Evaluation and Management of Older Patients with Breast Cancer
    Owusu, Cynthia
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 : S250 - S252
  • [25] Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk
    Schonberg, Mara A.
    Li, Vicky W.
    Eliassen, A. Heather
    Davis, Roger B.
    LaCroix, Andrea Z.
    McCarthy, Ellen P.
    Rosner, Bernard A.
    Chlebowski, Rowan T.
    Hankinson, Susan E.
    Marcantonio, Edward R.
    Ngo, Long H.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (03) : 547 - 562
  • [26] Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
    Gallagher, Christopher M.
    More, Kenneth
    Masaquel, Anthony
    Kamath, Tripthi
    Guerin, Annie
    Ionescu-Ittu, Raluca
    Nitulescu, Roy
    Gauthier-Loiselle, Marjolaine
    Sicignano, Nicholas
    Butts, Elizabeth
    Wu, Eric Q.
    Barnett, Brian
    SPRINGERPLUS, 2016, 5
  • [27] Association between age and survival in a cohort of Brazilian patients with operable breast cancer
    Balabram, Debora
    Turra, Cassio M.
    Gobbi, Helenice
    CADERNOS DE SAUDE PUBLICA, 2015, 31 (08): : 1732 - 1742
  • [28] Frailty-Independent Undertreatment Negative Impact on Survival in Older Patients With Breast Cancer
    Osorio, Fernando
    Barros, Antonio S.
    Peleteiro, Barbara
    Barradas, Ana Rita
    Urbano, Joana
    Fougo, Jose Luis
    Leite-Moreira, Adelino
    JOURNAL OF BREAST CANCER, 2021, 24 (06) : 542 - 553
  • [29] Surgery and survival in patients with stage IV breast cancer
    Arciero, Cletus
    Liu, Yuan
    Gillespie, Theresa
    Subhedar, Preeti
    BREAST JOURNAL, 2019, 25 (04) : 644 - 653
  • [30] Focusing on older patients with breast cancer
    Linz, Valerie Catherine
    Schmidt, Marcus
    Hasenburg, Annette
    GYNAKOLOGIE, 2025, : 277 - 285